Mylan and Biocon launch first Trastuzumab Biosimilar, Ogivri, in Australia
Ogivri is the first trastuzumab biosimilar approved and launched in Australia and available on the Pharmaceutical Benefits Scheme…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Home » Trastuzumab
Browsing Tag
Trastuzumab
Biocon Q1FY20 Revenue grows by 25 per cent
EBITDA up 51 per cent at Rs 462 crores, net profit (excluding exceptional item) up 86 per cent at Rs 223 crores, small molecules…